Page 2 - Celonic Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

By Syndicated Content By Ludwig Burger (Reuters) -CureVac said its COVID-19 vaccine was 48% effective in the final analysis of its pivotal mass trial, only marginally better than the 47% reported after an initial read-out two weeks ago. The German biotech firm said that efficacy, measured by preventing symptomatic disease, was slightly better at 53% when excluding trial participants older than 60 years, an age group that is by far the most severely affected. CureVac said on June 16 its COVID-19 vaccine, known as CVnCoV, proved only 47% effective in an initial trial read-out and that n...

CureVac fails in pivotal COVID-19 vaccine trial with 47% efficacy FILE PHOTO: A vaccination against the coronavirus disease (COVID-19) from German biotechnology company CureVac is ready to use at the start of a clinical test series in the tropical institute of the university clinic in Tuebingen, Germany, June 22, 2020. REUTERS/Kai Pfaffenbach June 17, 2021 By Ludwig Burger (Reuters) -German biotech CureVac NV said on Wednesday its COVID-19 vaccine was only 47% effective in a late-stage trial, missing the study’s main goal and throwing in doubt the potential delivery of hundreds of million...

DGAP-News: CureVac / Key word(s): Quarter Results/Annual Results CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020 15.04.2021 / 13:30 CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020 - COVID-19 vaccine candidate: CVnCoV in final stage of clinical development and believed to be well on track to provide data for conditional approval based on EMA rolling submission - Pivotal Phase 2b/3 in Europe and Latin America fully recruited with over 40,000 participants. Interim analysis for vaccine e...

CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020 - COVID-19 vaccine candidate: CVnCoV in final stage of clinical development and believed to be well on track to provide data for conditional approval based on EMA rolling submission - Pivotal Phase 2b/3 in Europe and Latin America fully recruited with over 40,000 participants. Interim analysis for vaccine efficacy expected in Q2 2021 - Phase 2a trial in Peru and Panama amended for addition of secondary endpoint for vaccine efficacy in total population with a focus on participants over the age...

By Reuters Staff 2 Min Read FILE PHOTO: A volunteer receives a dose of CureVac vaccine or a placebo during a study by the German biotech firm CureVac as part of a testing for a new vaccine against the coronavirus disease (COVID-19), in Brussels, Belgium March 2, 2021. REUTERS/Yves Herman/File Photo BERLIN (Reuters) - Global supply chains for making COVID-19 vaccines have been disrupted by U.S. restrictions, creating headaches for companies seeking to build production in Europe, according to one of the founders of Germany’s Curevac. Florian von der Muelbe said in a newspaper interview that h...